Compare Deutsche Bank AG (DB) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deutsche Bank AG vs Neurocrine Biosciences Inc — how do they compare? Deutsche Bank AG trades at $35.68 (market cap $67.54B), while Neurocrine Biosciences Inc trades at $170.05 (market cap $17.51B). The key difference: Deutsche Bank AG is far larger — about 3.9× Neurocrine Biosciences Inc's market cap, and Deutsche Bank AG pays a 3.3% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| DB | NBIX | |
|---|---|---|
Market Cap | $67.54B | $17.51B |
Sector | Financials | Health |
52-Week High | $40.33 | $180.55 |
52-Week Low | $28.37 | $123.10 |
Dividend Yield | 3.3% | — |
Enterprise Value | — | $16.60B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deutsche Bank AG
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
